CYDY
Price
$0.40
Change
+$0.06 (+17.65%)
Updated
May 9 closing price
Capitalization
491.74M
81 days until earnings call
RGLS
Price
$7.87
Change
+$0.02 (+0.25%)
Updated
May 9 closing price
Capitalization
544.53M
94 days until earnings call
Ad is loading...

CYDY vs RGLS

Header iconCYDY vs RGLS Comparison
Open Charts CYDY vs RGLSBanner chart's image
CytoDyn
Price$0.40
Change+$0.06 (+17.65%)
Volume$4.72M
Capitalization491.74M
Regulus Therapeutics
Price$7.87
Change+$0.02 (+0.25%)
Volume$1.65M
Capitalization544.53M
CYDY vs RGLS Comparison Chart
Loading...
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYDY vs. RGLS commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYDY is a Buy and RGLS is a Buy.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (CYDY: $0.40 vs. RGLS: $7.87)
Brand notoriety: CYDY and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYDY: 172% vs. RGLS: 70%
Market capitalization -- CYDY: $491.74M vs. RGLS: $544.53M
CYDY [@Biotechnology] is valued at $491.74M. RGLS’s [@Biotechnology] market capitalization is $544.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYDY’s FA Score shows that 1 FA rating(s) are green whileRGLS’s FA Score has 0 green FA rating(s).

  • CYDY’s FA Score: 1 green, 4 red.
  • RGLS’s FA Score: 0 green, 5 red.
According to our system of comparison, CYDY is a better buy in the long-term than RGLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYDY’s TA Score shows that 6 TA indicator(s) are bullish while RGLS’s TA Score has 4 bullish TA indicator(s).

  • CYDY’s TA Score: 6 bullish, 4 bearish.
  • RGLS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CYDY is a better buy in the short-term than RGLS.

Price Growth

CYDY (@Biotechnology) experienced а +22.81% price change this week, while RGLS (@Biotechnology) price change was +0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

CYDY is expected to report earnings on Jul 30, 2025.

RGLS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGLS($545M) has a higher market cap than CYDY($492M). RGLS YTD gains are higher at: 398.101 vs. CYDY (263.719). CYDY has higher annual earnings (EBITDA): -1.98M vs. RGLS (-45.85M). RGLS has more cash in the bank: 75.8M vs. CYDY (16.4M). RGLS has less debt than CYDY: RGLS (274K) vs CYDY (27.3M). CYDY (0) and RGLS (0) have equivalent revenues.
CYDYRGLSCYDY / RGLS
Capitalization492M545M90%
EBITDA-1.98M-45.85M4%
Gain YTD263.719398.10166%
P/E RatioN/AN/A-
Revenue00-
Total Cash16.4M75.8M22%
Total Debt27.3M274K9,964%
FUNDAMENTALS RATINGS
CYDY vs RGLS: Fundamental Ratings
CYDY
RGLS
OUTLOOK RATING
1..100
1831
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3434
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a14

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYDY's Valuation (4) in the null industry is somewhat better than the same rating for RGLS (61) in the Pharmaceuticals Other industry. This means that CYDY’s stock grew somewhat faster than RGLS’s over the last 12 months.

RGLS's Profit vs Risk Rating (81) in the Pharmaceuticals Other industry is in the same range as CYDY (100) in the null industry. This means that RGLS’s stock grew similarly to CYDY’s over the last 12 months.

RGLS's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CYDY (100) in the null industry. This means that RGLS’s stock grew similarly to CYDY’s over the last 12 months.

RGLS's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as CYDY (34) in the null industry. This means that RGLS’s stock grew similarly to CYDY’s over the last 12 months.

RGLS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CYDY (100) in the null industry. This means that RGLS’s stock grew similarly to CYDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYDYRGLS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 17 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

CYDY and

Correlation & Price change

A.I.dvisor tells us that CYDY and RGLS have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYDY and RGLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYDY
1D Price
Change %
CYDY100%
+19.10%
RGLS - CYDY
25%
Poorly correlated
+0.25%
TNXP - CYDY
22%
Poorly correlated
-0.58%
AGNPF - CYDY
21%
Poorly correlated
+15.38%
CLNN - CYDY
20%
Poorly correlated
+1.94%
GNNSF - CYDY
16%
Poorly correlated
N/A
More

RGLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGLS has been loosely correlated with ABEO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RGLS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
+0.25%
ABEO - RGLS
42%
Loosely correlated
-4.01%
NKTX - RGLS
32%
Poorly correlated
-1.03%
NAUT - RGLS
31%
Poorly correlated
-2.03%
ATOS - RGLS
31%
Poorly correlated
+0.85%
XENE - RGLS
30%
Poorly correlated
-1.46%
More